Protalix Biotherapeutics to Present at the Future Leaders in the Biotechnology Industry Conference
CARMIEL, Israel, April 1 /PRNewswire-FirstCall/ -- Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced today the Company will participate in the Future Leaders in the Biotechnology Industry Conference, to be held on April 8, 2010 in New York City. Yossi Maimon, the Company's CFO, will present a 25 minute corporate overview at 4:30 PM ET.
An audio webcast of the corporate presentation will be available on Protalix's website at www.protalix.com under the events calendar section.
About Protalix
Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that the Company believes will allow for the industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. In August 2009, the FDA granted orphan drug status and fast track designation to taliglucerase alfa for the treatment of Gaucher disease and Protalix filed a rolling NDA submission with the FDA in December 2009. In November 2009, Protalix granted Pfizer Inc. exclusive, worldwide rights to develop and commercialize taliglucerase alfa for the treatment of Gaucher disease, except in Israel. Protalix retained the right to commercialize taliglucerase alfa in Israel.
Safe Harbor Statement:
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes and are valid only as of the date hereof. We disclaim any obligation to update this information except to the extent required by law.
Investor Contact: |
|
Marcy Nanus |
|
The Trout Group, LLC |
|
Telephone: 646-378-2927 |
|
Email: [email protected] |
|
Media Contact: |
|
Brad Miles |
|
BMC Communications Group, LLC |
|
Telephone: 212-477-9007 x17 |
|
Email: [email protected] |
|
SOURCE Protalix Biotherapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article